Skip to main content
Premium Trial:

Request an Annual Quote



In the 12/21/01 article “Could Microarrays Replace Sequencers? Callida Genomics Thinks So,” Rade Drmanac, the chief scientific officer of Callida, was erroneously referred to as the chief executive officer. Also, Hyseq owns more than the 50 percent share of Callida indicated in the article, and Affymetrix provided an undisclosed sum to the company, not exactly $1.5 million.


In the 2/22/02 issue, the Patent Watch stated that Arcturus’ RiboAmp RNA Amplification Kit sells for a list price of $1,125. This is out of date: Since November 2001, the kit has sold for a list price of $695.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.